TURN.BIO
Turn.bio is a biotechnology company developing drugs to reverse aging and age-related diseases. Utilizing a patented mRNA platform technology, ERA, the company is combating the effects of aging on the epigenome. The company’s proprietary mRNA platform technology, ERA and eTurna, a delivery platform specifically designed to enable nucleic acid therapeutics, combats the effects of aging in the epigenome, thus restoring optimal gene expression. It focuses on developing tailored therapies targeting indications in immune-related diseases like cancer and dermatological conditions, as well as therapies for ophthalmology, osteoarthritis, and the muscular system.
TURN.BIO
Industry:
Biotechnology Genetics Health Care Life Science Therapeutics
Founded:
2019-02-01
Address:
Mountain View, California, United States
Country:
United States
Website Url:
http://www.turn.bio
Total Employee:
11+
Status:
Active
Contact:
+1 833 877 6246
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta SPF Google Font API Content Delivery Network LetsEncrypt SSL By Default HSTS Google Apps For Business YouTube GoDaddy DNS
Similar Organizations
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Flightpath Biosciences
Flightpath Biosciences is a biotechnology company that develops medications to treat rare infectious diseases.
Gritstone Bio
Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Teal Omics
Teal Omics is a biotechnology company building an AI-enabled proteomics platform to discover novel targets of aging and age-related disease.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Walden Biosciences
Walden Biosciences is a biotechnology company focused on transforming the treatment of kidney disease.
Current Employees Featured
Founder
Investors List
ThreeD Capital
ThreeD Capital investment in Venture Round - Turn.bio
HanAll Biopharma
HanAll Biopharma investment in Venture Round - Turn.bio
Daewoong Pharmaceutical
Daewoong Pharmaceutical investment in Venture Round - Turn.bio
Astellas Venture Management
Astellas Venture Management investment in Venture Round - Turn.bio
LongeVC
LongeVC investment in Venture Round - Turn.bio
Formic Ventures
Formic Ventures investment in Venture Round - Turn.bio
Shanda Group
Shanda Group investment in Venture Round - Turn.bio
Methuselah Funds
Methuselah Funds investment in Venture Round - Turn.bio
Khosla Ventures
Khosla Ventures investment in Venture Round - Turn.bio
Shanda Group
Shanda Group investment in Venture Round - Turn.bio
Key Employee Changes
| Date | New article |
|---|---|
| 2022-11-02 | Turn Biotechnologies Names 25-year Biotech Industry Veteran Richard Peterson Chief Financial Officer |
Official Site Inspections
http://www.turn.bio Semrush global rank: 4.91 M Semrush visits lastest month: 1.75 K
- Host name: 198.185.159.144
- IP address: 198.185.159.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Turn.bio"
Turn.bio - Crunchbase Company Profile & Funding
Organization. Turn.bio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Turn.bio is a biotechnology company …See details»
About — turn.bio
Former Turn CEO, Gary is executive chairman and co-founder of Oisín Biotechnologies, which is researching ways to mitigate the effects of age-related diseases by addressing damage created by the aging process. Gary is active …See details»
Turn.bio - Funding, Financials, Valuation & Investors - Crunchbase
Turn.bio has raised 4 rounds. Their latest funding was raised on Apr 11, 2022 from a Venture - Series Unknown round. Turn.bio is funded by 11 investors. ThreeD Capital and HanAll …See details»
VitaDAO Invests $1 Million into Biotech Company Turn.Bio - lifespan
turn.bio 2025 Company Profile: Valuation, Funding
Turn.bio General Information Description. Developer of longevity drugs designed to reverse aging and age-related diseases. The company's drugs induce the body to heal itself by instructing specific cells to fight disease or repair damaged …See details»
Executive Team — turn.bio
©2022 Turn biotechnologies, inc. MAILING/BILLING ADDRESS: 548 Market St. PMB 23131, San Francisco, CA 94104 LAB ADDRESS: 319 N. Bernardo Ave., Mountain View, CA 94043 +1- ...See details»
Turn Bio - Longevity List
Turn Bio’s goal is to address multiple aging-related indications using a single powerful reprogramming therapy that turns old cells young again, aiding in the rejuvenation of an aged …See details»
Turn.bio - Updates, News, Events, Signals & Triggers - Crunchbase
Turn.bio has entered into a global licensing agreement with HanAll Biopharma to develop treatments for age-related eye and ear diseases, focusing on epigenetic reprogramming. This …See details»
Cell Rejuvenation Trailblazer Turn Bio Closes Funding Round ...
May 3, 2022 Turn Bio is an example of our “debug the code” strategy, which recognizes that humans are built from codes, including DNA and the “action code,” RNA. As we go through …See details»
mRNA cell rejuvenation approaches clinic | Lifespan.io
Oct 25, 2023 The results of the INTERACT meeting mean that Turn Bio is well positioned to be the first company to take a cell rejuvenation therapy to clinical trials. ... Lifespan Research …See details»
Turn.bio: Transiently Reprogramming Cells to Near Pluripotence as …
Mar 19, 2019 Turn.bio is Gary Hudson's latest company, now that others are running the day to day development at Oisin Biotechnologies.The Turn.bio staff are working on a particular take …See details»
Turn Bio announce worldwide IP for mRNA tech
Jan 12, 2021 Turn Biotechnologies, a company developing medicines for currently untreatable age-related conditions, has today announced that it has acquired the global rights for new …See details»
Investors — turn.bio
NEXT - THE SCIENCE BEHIND TURN Legal Disclaimer Contact Us ©2022 Turn biotechnologies, inc. MAILING/BILLING ADDRESS: 548 Market St. PMB 23131, San Francisco, CA 94104 LAB …See details»
Turn Bio adds veteran executives with decades of international …
MOUNTAIN VIEW, Calif., March 7, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure now-untreatable, chronic, …See details»
Turn.bio - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Turn.bio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 5. Contacts 21. ... Turn.bio …See details»
Turn Bio commences bone marrow rejuvenation study
Dec 3, 2024 Cell rejuvenation company Turn Biotechnologies has announced the launch of a new preclinical study aimed at evaluating the effectiveness of its epigenetic reprogramming …See details»
Opportunities — turn.bio
Turn Biotechnology is proud to work with a group of investors that share the company’s vision of developing trailblazing treatments for age-related diseases for which no efficacious treatment …See details»
New survey: U.S. biotechs warn tariffs could impede access to …
2 days ago WASHINGTON (March 26, 2025) -- Today, the Biotechnology Innovation Organization (BIO) released results from a membership survey that underscores the …See details»
Turn Bio adds veteran executives with decades of international …
MOUNTAIN VIEW, Calif., March 7, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure now-untreatable, chronic, …See details»
How to Lead a Successful Turnaround - Harvard Business Review
1 day ago My organization, I didn’t make any mistakes, etc.,” I pretty much thought they wouldn’t make the cut long. And that’s generally how it worked out. So right away, I am, if you will ...See details»